microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer
microRNA expression profiling plays an emerging role in cancer classification and identification of therapeutic strategies. In this study, we have evaluated the benefits of a joint microRNA-mRNA analysis in breast cancer. Matched mRNA and microRNA global expression profiling was conducted in a well-...
Saved in:
| Published in: | Cancer research (Chicago, Ill.) Vol. 71; no. 17; p. 5635 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
01.09.2011
|
| Subjects: | |
| ISSN: | 1538-7445, 1538-7445 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | microRNA expression profiling plays an emerging role in cancer classification and identification of therapeutic strategies. In this study, we have evaluated the benefits of a joint microRNA-mRNA analysis in breast cancer. Matched mRNA and microRNA global expression profiling was conducted in a well-annotated cohort of 207 cases with complete 10-year follow-up. Penalized Cox regression including microRNA expression, mRNA expression, and clinical covariates was used to identify microRNAs associated with distant relapse-free survival (DRFS) that provide independent prognostic information, and are not simply surrogates of previously identified prognostic covariates. Penalized regression was chosen to prevent overfitting. Furthermore, microRNA-mRNA relationships were explored by global expression analysis, and exploited to validate results in several published cohorts (n = 592 with DRFS, n = 1,050 with recurrence-free survival). Four microRNAs were independently associated with DRFS in estrogen receptor (ER)-positive (3 novel and 1 known; miR-128a) and 6 in ER-negative (5 novel and 1 known; miR-210) cases. Of the latter, miR-342, -27b, and -150 were prognostic also in triple receptor-negative tumors. Coordinated expression of predicted target genes and prognostic microRNAs strengthened these results, most significantly for miR-210, -128a, and -27b, whose targets were prognostic in meta-analysis of several cohorts. In addition, miR-210 and -128a showed coordinated expression with their cognate pri-microRNAs, which were themselves prognostic in independent cohorts. Our integrated microRNA-mRNA global profiling approach has identified microRNAs independently associated with prognosis in breast cancer. Furthermore, it has validated known and predicted microRNA-target interactions, and elucidated their association with key pathways that could represent novel therapeutic targets. |
|---|---|
| AbstractList | microRNA expression profiling plays an emerging role in cancer classification and identification of therapeutic strategies. In this study, we have evaluated the benefits of a joint microRNA-mRNA analysis in breast cancer. Matched mRNA and microRNA global expression profiling was conducted in a well-annotated cohort of 207 cases with complete 10-year follow-up. Penalized Cox regression including microRNA expression, mRNA expression, and clinical covariates was used to identify microRNAs associated with distant relapse-free survival (DRFS) that provide independent prognostic information, and are not simply surrogates of previously identified prognostic covariates. Penalized regression was chosen to prevent overfitting. Furthermore, microRNA-mRNA relationships were explored by global expression analysis, and exploited to validate results in several published cohorts (n = 592 with DRFS, n = 1,050 with recurrence-free survival). Four microRNAs were independently associated with DRFS in estrogen receptor (ER)-positive (3 novel and 1 known; miR-128a) and 6 in ER-negative (5 novel and 1 known; miR-210) cases. Of the latter, miR-342, -27b, and -150 were prognostic also in triple receptor-negative tumors. Coordinated expression of predicted target genes and prognostic microRNAs strengthened these results, most significantly for miR-210, -128a, and -27b, whose targets were prognostic in meta-analysis of several cohorts. In addition, miR-210 and -128a showed coordinated expression with their cognate pri-microRNAs, which were themselves prognostic in independent cohorts. Our integrated microRNA-mRNA global profiling approach has identified microRNAs independently associated with prognosis in breast cancer. Furthermore, it has validated known and predicted microRNA-target interactions, and elucidated their association with key pathways that could represent novel therapeutic targets. microRNA expression profiling plays an emerging role in cancer classification and identification of therapeutic strategies. In this study, we have evaluated the benefits of a joint microRNA-mRNA analysis in breast cancer. Matched mRNA and microRNA global expression profiling was conducted in a well-annotated cohort of 207 cases with complete 10-year follow-up. Penalized Cox regression including microRNA expression, mRNA expression, and clinical covariates was used to identify microRNAs associated with distant relapse-free survival (DRFS) that provide independent prognostic information, and are not simply surrogates of previously identified prognostic covariates. Penalized regression was chosen to prevent overfitting. Furthermore, microRNA-mRNA relationships were explored by global expression analysis, and exploited to validate results in several published cohorts (n = 592 with DRFS, n = 1,050 with recurrence-free survival). Four microRNAs were independently associated with DRFS in estrogen receptor (ER)-positive (3 novel and 1 known; miR-128a) and 6 in ER-negative (5 novel and 1 known; miR-210) cases. Of the latter, miR-342, -27b, and -150 were prognostic also in triple receptor-negative tumors. Coordinated expression of predicted target genes and prognostic microRNAs strengthened these results, most significantly for miR-210, -128a, and -27b, whose targets were prognostic in meta-analysis of several cohorts. In addition, miR-210 and -128a showed coordinated expression with their cognate pri-microRNAs, which were themselves prognostic in independent cohorts. Our integrated microRNA-mRNA global profiling approach has identified microRNAs independently associated with prognosis in breast cancer. Furthermore, it has validated known and predicted microRNA-target interactions, and elucidated their association with key pathways that could represent novel therapeutic targets.microRNA expression profiling plays an emerging role in cancer classification and identification of therapeutic strategies. In this study, we have evaluated the benefits of a joint microRNA-mRNA analysis in breast cancer. Matched mRNA and microRNA global expression profiling was conducted in a well-annotated cohort of 207 cases with complete 10-year follow-up. Penalized Cox regression including microRNA expression, mRNA expression, and clinical covariates was used to identify microRNAs associated with distant relapse-free survival (DRFS) that provide independent prognostic information, and are not simply surrogates of previously identified prognostic covariates. Penalized regression was chosen to prevent overfitting. Furthermore, microRNA-mRNA relationships were explored by global expression analysis, and exploited to validate results in several published cohorts (n = 592 with DRFS, n = 1,050 with recurrence-free survival). Four microRNAs were independently associated with DRFS in estrogen receptor (ER)-positive (3 novel and 1 known; miR-128a) and 6 in ER-negative (5 novel and 1 known; miR-210) cases. Of the latter, miR-342, -27b, and -150 were prognostic also in triple receptor-negative tumors. Coordinated expression of predicted target genes and prognostic microRNAs strengthened these results, most significantly for miR-210, -128a, and -27b, whose targets were prognostic in meta-analysis of several cohorts. In addition, miR-210 and -128a showed coordinated expression with their cognate pri-microRNAs, which were themselves prognostic in independent cohorts. Our integrated microRNA-mRNA global profiling approach has identified microRNAs independently associated with prognosis in breast cancer. Furthermore, it has validated known and predicted microRNA-target interactions, and elucidated their association with key pathways that could represent novel therapeutic targets. |
| Author | Taylor, Marian Winchester, Laura Gee, Harriet E Camps, Carme Sheldon, Helen Ragoussis, Jiannis Snell, Cameron E Harris, Adrian L Buffa, Francesca M |
| Author_xml | – sequence: 1 givenname: Francesca M surname: Buffa fullname: Buffa, Francesca M organization: Oncology Department, Weatherall Institute of Molecular Medicine, University of Oxford and Genomics Research, Wellcome Trust Centre for Human Genetics, Oxford, UK – sequence: 2 givenname: Carme surname: Camps fullname: Camps, Carme – sequence: 3 givenname: Laura surname: Winchester fullname: Winchester, Laura – sequence: 4 givenname: Cameron E surname: Snell fullname: Snell, Cameron E – sequence: 5 givenname: Harriet E surname: Gee fullname: Gee, Harriet E – sequence: 6 givenname: Helen surname: Sheldon fullname: Sheldon, Helen – sequence: 7 givenname: Marian surname: Taylor fullname: Taylor, Marian – sequence: 8 givenname: Adrian L surname: Harris fullname: Harris, Adrian L – sequence: 9 givenname: Jiannis surname: Ragoussis fullname: Ragoussis, Jiannis |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/21737487$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkFtLAzEQhYMoWqs_QcmbT1tz2WzSx1K8gVQQfS7Z7KSN7GbXJEX7W_yzxnrBpxmYc74znGO073sPCJ1RMqFUqEtCiCpEKdlkPlsUlBakVNM9NKKCq0KWpdj_tx-h4xhfskVQIg7REaOSy1LJEfronAn942JW6Bh743SCBg-hXwWI0fUeDzqt3_Q2Yu3zoU_gk9MtTmsIeoBNcgYnHVaQInbN19G6TKi32PkEq7DjdZm_8_-GYXgf_gJCb13r_Co7cB1Ax4SN9gbCCTqwuo1w-jPH6Pn66ml-W9w_3NzNZ_eFKblMRc05qyQnYLlktWW8nmrVyEroXAkRUyNBV4wp1kgrGqgtEbyi1oAlla0MZWN08c3Nr7xuIKZl56KBttUe-k1cKiUFkTkhK89_lJu6g2Y5BNfpsF3-9sk-Aco0fkw |
| CitedBy_id | crossref_primary_10_3892_ol_2015_3831 crossref_primary_10_1016_j_molonc_2016_07_004 crossref_primary_10_1016_j_canlet_2014_11_050 crossref_primary_10_1186_1756_9966_33_50 crossref_primary_10_1245_s10434_018_6859_x crossref_primary_10_1038_emboj_2011_368 crossref_primary_10_1038_bjc_2013_240 crossref_primary_10_1186_1476_4598_13_28 crossref_primary_10_1038_s41598_019_51581_3 crossref_primary_10_1093_carcin_bgx022 crossref_primary_10_4236_eng_2013_510B011 crossref_primary_10_3390_cells13181518 crossref_primary_10_1038_onc_2012_128 crossref_primary_10_1371_journal_pone_0084859 crossref_primary_10_1016_j_mce_2020_110866 crossref_primary_10_1038_srep35773 crossref_primary_10_1186_s12859_015_0680_3 crossref_primary_10_1007_s13206_013_7101_3 crossref_primary_10_1038_srep14499 crossref_primary_10_1186_s12918_015_0211_x crossref_primary_10_1007_s10549_016_4013_7 crossref_primary_10_1002_cam4_442 crossref_primary_10_1124_mol_114_092759 crossref_primary_10_1016_j_steroids_2011_12_016 crossref_primary_10_15252_msb_202110558 crossref_primary_10_1007_s10911_012_9244_6 crossref_primary_10_3390_ijms161226090 crossref_primary_10_1038_onc_2012_361 crossref_primary_10_1371_journal_pone_0039011 crossref_primary_10_1186_s12935_018_0642_8 crossref_primary_10_1186_s12864_017_3498_8 crossref_primary_10_1016_j_molonc_2014_07_023 crossref_primary_10_1158_1078_0432_CCR_14_2053 crossref_primary_10_1158_0008_5472_CAN_13_0158 crossref_primary_10_1158_0008_5472_CAN_13_0704 crossref_primary_10_1371_journal_pcbi_1003351 crossref_primary_10_2217_pgs_12_15 crossref_primary_10_1007_s11523_016_0432_y crossref_primary_10_3390_ijms141122202 crossref_primary_10_1186_1755_8794_7_S1_S10 crossref_primary_10_3892_ol_2016_5295 crossref_primary_10_3390_ijms18010194 crossref_primary_10_1186_1477_5956_10_S1_S15 crossref_primary_10_1002_iub_2726 crossref_primary_10_1016_j_semcancer_2020_09_007 crossref_primary_10_1186_s13058_019_1098_z crossref_primary_10_1016_j_jpba_2014_10_018 crossref_primary_10_1097_MD_0000000000007085 crossref_primary_10_1038_s41388_022_02409_4 crossref_primary_10_1158_0008_5472_CAN_13_3429 crossref_primary_10_1158_0008_5472_CAN_14_2394 crossref_primary_10_3233_BD_201076 crossref_primary_10_1145_3365673 crossref_primary_10_1016_j_gene_2020_145113 crossref_primary_10_1186_1471_2164_13_S7_S18 crossref_primary_10_1038_bjc_2015_206 crossref_primary_10_1038_ncomms6671 crossref_primary_10_18632_oncotarget_5128 crossref_primary_10_1186_s13058_014_0436_4 crossref_primary_10_1007_s00018_022_04333_y crossref_primary_10_1038_s41540_019_0090_7 crossref_primary_10_1016_j_cell_2013_06_026 crossref_primary_10_1016_j_gene_2018_01_070 crossref_primary_10_1186_bcr3693 crossref_primary_10_1186_1471_2164_14_643 crossref_primary_10_1093_nar_gky286 crossref_primary_10_1007_s10549_019_05192_1 crossref_primary_10_1186_s12943_017_0673_0 crossref_primary_10_14309_ctg_0000000000000579 crossref_primary_10_3389_fonc_2024_1499950 crossref_primary_10_1109_TCBB_2021_3076422 crossref_primary_10_1038_bjc_2014_236 crossref_primary_10_1007_s12672_025_02246_3 crossref_primary_10_3390_cancers12030632 crossref_primary_10_1007_s10549_014_3004_9 crossref_primary_10_1016_j_heliyon_2024_e27011 crossref_primary_10_1016_j_semcancer_2018_01_007 crossref_primary_10_1186_bcr3686 crossref_primary_10_1038_nature11207 crossref_primary_10_1371_journal_pone_0048692 crossref_primary_10_1038_nm_3497 crossref_primary_10_1016_j_cytogfr_2015_07_015 crossref_primary_10_3390_genes10030200 crossref_primary_10_1158_0008_5472_CAN_13_1960 crossref_primary_10_1007_s10549_012_2346_4 crossref_primary_10_1016_j_gene_2012_07_025 crossref_primary_10_1186_s12864_017_3790_7 crossref_primary_10_1186_s12885_016_2840_x crossref_primary_10_1186_s12951_020_00767_3 crossref_primary_10_3389_fimmu_2021_715508 crossref_primary_10_1007_s10549_017_4132_9 crossref_primary_10_1177_1010428317692204 crossref_primary_10_3892_ijo_2014_2487 crossref_primary_10_1186_s12920_025_02194_5 crossref_primary_10_3389_fimmu_2022_818173 crossref_primary_10_1007_s11033_014_3305_4 crossref_primary_10_1016_j_gene_2019_144301 crossref_primary_10_1586_14760584_2013_845530 crossref_primary_10_1038_s41598_019_55710_w crossref_primary_10_1631_jzus_B1400184 crossref_primary_10_1002_mc_23203 crossref_primary_10_1038_s41540_024_00486_7 crossref_primary_10_3892_mmr_2016_4940 crossref_primary_10_1371_journal_pone_0087039 crossref_primary_10_1038_onc_2012_11 crossref_primary_10_1002_wrna_1563 crossref_primary_10_1038_ncomms2393 crossref_primary_10_1093_humrep_deu332 crossref_primary_10_1038_bjc_2013_765 crossref_primary_10_1186_gb_2014_15_1_r9 crossref_primary_10_1038_nature12108 crossref_primary_10_1371_journal_pone_0077124 crossref_primary_10_1016_j_ajpath_2013_02_046 crossref_primary_10_1111_brv_12176 crossref_primary_10_3390_jpm12101750 crossref_primary_10_3389_fgene_2019_00790 crossref_primary_10_4137_CIN_S9037 crossref_primary_10_1007_BF03262205 crossref_primary_10_1038_srep32541 crossref_primary_10_1038_cddis_2017_364 crossref_primary_10_1038_s41418_023_01140_1 crossref_primary_10_1093_nar_gkt525 crossref_primary_10_1371_journal_pone_0064273 crossref_primary_10_1007_s11033_012_2442_x crossref_primary_10_1371_journal_pone_0126837 crossref_primary_10_1586_14737159_2014_901153 crossref_primary_10_1007_s10552_013_0187_z crossref_primary_10_1002_path_4363 crossref_primary_10_1155_2013_290568 crossref_primary_10_1371_journal_pone_0076247 crossref_primary_10_3892_ijo_2015_2821 crossref_primary_10_1158_0008_5472_CAN_18_0069 crossref_primary_10_2147_OTT_S234443 crossref_primary_10_1186_s12935_021_01957_1 crossref_primary_10_1038_srep21735 crossref_primary_10_7717_peerj_9422 crossref_primary_10_3892_mmr_2025_13619 crossref_primary_10_1016_j_compbiomed_2017_06_005 crossref_primary_10_1634_theoncologist_2019_0123 crossref_primary_10_4161_cc_25405 crossref_primary_10_1109_ACCESS_2020_3018148 crossref_primary_10_1158_1078_0432_CCR_18_0776 crossref_primary_10_1016_j_ijrobp_2016_01_025 crossref_primary_10_1093_ecco_jcc_jjac027 crossref_primary_10_1586_erm_11_69 crossref_primary_10_5306_wjco_v5_i3_323 crossref_primary_10_1016_j_ctrv_2020_102019 crossref_primary_10_1038_onc_2013_306 crossref_primary_10_2147_BCTT_S282860 crossref_primary_10_1186_s13058_016_0673_9 crossref_primary_10_1016_j_biocel_2015_02_018 crossref_primary_10_1038_onc_2017_247 crossref_primary_10_1016_j_gene_2012_11_056 crossref_primary_10_3389_fgene_2015_00072 crossref_primary_10_1186_s12885_017_3827_y crossref_primary_10_1007_s00018_012_1128_9 crossref_primary_10_1093_bib_bbz116 crossref_primary_10_1586_erm_12_21 crossref_primary_10_1586_era_12_11 crossref_primary_10_1038_ncb2672 crossref_primary_10_1186_s12859_021_04215_3 crossref_primary_10_1038_srep06566 crossref_primary_10_1158_0008_5472_CAN_16_3105 crossref_primary_10_1371_journal_pone_0100664 crossref_primary_10_1186_bcr3176 crossref_primary_10_1096_fj_201800120R crossref_primary_10_1038_srep15832 crossref_primary_10_1073_pnas_1210353110 crossref_primary_10_1016_j_canlet_2014_07_036 crossref_primary_10_1007_s12672_012_0102_1 crossref_primary_10_1038_ncb3533 crossref_primary_10_1089_ars_2013_5648 crossref_primary_10_1158_0008_5472_CAN_19_2207 crossref_primary_10_1073_pnas_1304977110 crossref_primary_10_1038_nrd2372 crossref_primary_10_1016_j_lfs_2023_122183 crossref_primary_10_1089_ars_2013_5639 crossref_primary_10_1634_theoncologist_2014_0184 crossref_primary_10_3892_ijmm_2019_4239 crossref_primary_10_3109_14756366_2014_966704 crossref_primary_10_1186_1471_2407_14_57 crossref_primary_10_1371_journal_pone_0031615 crossref_primary_10_1186_s12885_015_1740_9 crossref_primary_10_3892_or_2015_4173 crossref_primary_10_1155_2019_2316237 crossref_primary_10_1186_s12859_018_2070_0 crossref_primary_10_1016_j_neo_2023_100942 crossref_primary_10_1016_j_gene_2014_11_047 crossref_primary_10_1038_s41598_022_26000_9 crossref_primary_10_1186_1471_2105_16_S5_S5 crossref_primary_10_3892_ijo_2015_3161 crossref_primary_10_1038_bjc_2017_105 crossref_primary_10_1007_s13402_019_00450_2 crossref_primary_10_1088_1361_6560_aa7c55 crossref_primary_10_1016_j_compbiolchem_2019_107191 crossref_primary_10_1038_s41467_018_07657_1 crossref_primary_10_1371_journal_pone_0101656 crossref_primary_10_1016_j_ijrobp_2015_08_046 crossref_primary_10_1038_s41598_018_29708_9 crossref_primary_10_15252_embr_201540678 crossref_primary_10_1186_1471_2407_14_51 crossref_primary_10_1038_nature10730 crossref_primary_10_3390_biom10010150 |
| ContentType | Journal Article |
| Copyright | 2011 AACR |
| Copyright_xml | – notice: 2011 AACR |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/0008-5472.CAN-11-0489 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-7445 |
| ExternalDocumentID | 21737487 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Wellcome Trust grantid: 090532 – fundername: Cancer Research UK grantid: 11359 |
| GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 3O- 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC ABOCM ACGFO ACIWK ACPRK ADBBV ADCOW AENEX AETEA AFFNX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 EBS ECM EIF EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO NPM OK1 P0W P2P PQQKQ RCR RHI RNS SJN TR2 UDS W2D W8F WH7 WOQ YKV YZZ 7X8 ABUFD |
| ID | FETCH-LOGICAL-c437t-b3326730ef372bf23b9a8d765a048059c7ea62282d7f5debf05361fcef06f6c12 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 256 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000294454700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1538-7445 |
| IngestDate | Sun Nov 09 11:37:24 EST 2025 Mon Jul 21 05:50:57 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Language | English |
| License | 2011 AACR |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c437t-b3326730ef372bf23b9a8d765a048059c7ea62282d7f5debf05361fcef06f6c12 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 21737487 |
| PQID | 887507730 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_887507730 pubmed_primary_21737487 |
| PublicationCentury | 2000 |
| PublicationDate | 2011-09-01 |
| PublicationDateYYYYMMDD | 2011-09-01 |
| PublicationDate_xml | – month: 09 year: 2011 text: 2011-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer research (Chicago, Ill.) |
| PublicationTitleAlternate | Cancer Res |
| PublicationYear | 2011 |
| References | 22369323 - Expert Rev Anticancer Ther. 2012 Mar;12(3):323-30. doi: 10.1586/era.12.11. |
| References_xml | – reference: 22369323 - Expert Rev Anticancer Ther. 2012 Mar;12(3):323-30. doi: 10.1586/era.12.11. |
| SSID | ssj0005105 |
| Score | 2.511284 |
| Snippet | microRNA expression profiling plays an emerging role in cancer classification and identification of therapeutic strategies. In this study, we have evaluated... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 5635 |
| SubjectTerms | Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Disease Progression Disease-Free Survival Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans MicroRNAs - genetics Neoplasm Recurrence, Local - genetics Prognosis RNA, Messenger - genetics |
| Title | microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/21737487 https://www.proquest.com/docview/887507730 |
| Volume | 71 |
| WOSCitedRecordID | wos000294454700007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1Fe8sBqaB6OnQlVFRUDjSoEqFtkJ7bUoUlpwqO_hT_L2XELEwwoUhbr7MS-O9_Z390hdKk7THNoJCqXkoScKsJNCteO4oGOmJbMlnt7vmdJwkejeOiwOZWDVS50olXUeZmZM_JrEAYwXYAfb6YvxBSNMperroLGKmoFYMkYpmaj72ThtEEwWplmYUhdAI9HuYlf4ISGzL_qdRMbWhbyX4xMu9n0t__5mTtoy1mZuNuwxS5aUcUe2hi4e_R99DkxOLyHpEuEWx6VYwvVatJ0YFOo-F3MKywKaChrgymCDn9Ea-EGQ17hcd4AjqAHOcfL9BM5nkD_ln4xGFYf0-UAtlY47JtAgaVBxtc4Mxw4O0BP_dvH3h1xZRpIFgasJjIAExD-WOmA-VL7gYwFz1lEhYlXp3HGlIh8cO1ypmmupAa5jzydKd2JdJR5_iFaK8pCHSMsGDzCk1mg41ABHdeRApcQtIpkgaRthBeznoIYmLsNUajytUqX895GR83KpdMmXUcKTpfJscNO_iY-RZvNmbHBkJ2hlgYVoM7RevZWj6vZhWUveCfDwRed1d2_ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=microRNA-associated+progression+pathways+and+potential+therapeutic+targets+identified+by+integrated+mRNA+and+microRNA+expression+profiling+in+breast+cancer&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Buffa%2C+Francesca+M&rft.au=Camps%2C+Carme&rft.au=Winchester%2C+Laura&rft.au=Snell%2C+Cameron+E&rft.date=2011-09-01&rft.eissn=1538-7445&rft.volume=71&rft.issue=17&rft.spage=5635&rft_id=info:doi/10.1158%2F0008-5472.CAN-11-0489&rft_id=info%3Apmid%2F21737487&rft_id=info%3Apmid%2F21737487&rft.externalDocID=21737487 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7445&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7445&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7445&client=summon |